Cambridge Cognition aims for FDA nod in schizophrenia care

Published 18/02/2025, 08:14
Cambridge Cognition aims for FDA nod in schizophrenia care

LONDON - Cambridge Cognition Holdings (LON:COGC) plc (AIM: COG), a company specializing in brain health software for clinical research and patient treatment, has announced the submission of a Letter of Intent to the U.S. Food and Drug Administration (FDA) as part of the Drug Development Tool pathway. This submission is a step towards developing an objective and reliable measure of cognitive impairment associated with schizophrenia (CIAS).

The FDA has acknowledged the potential for CIAS improvement to serve as a co-primary outcome in schizophrenia clinical trials. Cambridge Cognition's move is in response to the increasing awareness of cognitive symptoms as an essential focus for treatment in schizophrenia. CIAS impacts critical functions such as memory, attention, and problem-solving, and can present early in the disease, often hindering patients' ability to work, maintain relationships, and live independently.

Cambridge Cognition's proposed digital cognitive assessment tool aims to provide scalable assessments of core cognitive domains affected in schizophrenia. This approach could offer advantages over traditional methods, including increased sensitivity, reliability, and ease of use. The company's strategy is based on positive exploratory results from the use of these assessments in a recent Phase III clinical trial involving schizophrenia patients.

Rob Baker, Joint Managing Director and Chief Operating Officer of Cambridge Cognition, expressed optimism about the submission, stating that it represents a significant step in addressing the need for improved cognitive assessment in schizophrenia. He emphasized that, while the regulatory process is still in its early stages, the company's scientific foundation and clinical evidence base could lead to productive discussions with the FDA.

The company has committed to providing further updates as the regulatory process progresses. This development could potentially streamline clinical trials and hasten the creation of targeted treatments for schizophrenia, specifically addressing the persistent and debilitating cognitive impairments that significantly impact patient functionality.

The information in this article is based on a press release statement from Cambridge Cognition Holdings plc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.